Key Protein in Parkinson’s – Alpha-synuclein – Travels from Gut to Clump in Brain, Study Reports
Altered forms of the alpha-synuclein protein travel along the vagus nerve from the gut to the brain where they accumulate,…
Articles by José Lopes, PhD
Accordion Pill Can Ease Motor Fluctuations in People with Advanced Disease, Phase 2 Data Show
Oral treatment with Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) lessened the variability of levodopa plasma levels and eased motor fluctuations in people…
CYP2D6 Enzyme Could Be Therapeutic Target in Parkinson’s, Study Suggests
Blocking an enzyme that converts compounds derived from certain foods and tobacco in the brain may become a therapeutic target…
Ultrasound Approach Eases Dopaminergic Brain Damage in Mouse Model of Parkinson’s
Using ultrasound coupled with the intravenous injection of microbubbles lessened brain damage in a mouse model of early Parkinson’s…
Alpha-synuclein in Blood Serum May Be Early Parkinson’s Biomarker, Study Suggests
Measuring the amount of alpha-synuclein in tiny vesicles collected from blood serum may help diagnose early Parkinson’s and identify patients…
Patients with Bipolar Disorder at Higher Risk of Developing Parkinson’s, Study Suggests
Patients with bipolar disorder appear to have a nearly seven times higher risk of developing Parkinson’s disease later…
#AANAM – Stem Cell Therapy Seen as Safe, May Improve Motor Function, Early Findings Suggest
Treatment with mesenchymal stem cells (MSCs) — adult stem cells with regenerative effects — is safe and well-tolerated, and…
Growing LRRK2 Protein Crystals in Space Could Help Scientists Better Understand and Treat Parkinson’s
Crystals of the LRRK2 protein grown aboard the International Space Station could improve the understanding of Parkinson’s disease and help…
Mild Cognitive Impairment in Parkinson’s Linked to Worse Memory, Attention Deficits, Study Reports
Parkinson’s disease patients with mild cognitive impairment (MCI) have a lower quality of life if their memory is…
ITI-214 Safe, Well-tolerated in Mild to Moderate Parkinson’s Patients, Phase 1/2 Trial Shows
Treatment with the experimental oral therapy ITI-214 was safe and well-tolerated in patients with mild to moderate Parkinson’s disease,…